Detalhe da pesquisa
1.
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Br J Haematol
; 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504552
2.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414019
3.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622738
4.
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Future Oncol
; 18(40): 4443-4456, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36799429
5.
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Cancer
; 127(22): 4198-4212, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34314018
6.
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Br J Haematol
; 194(3): 496-507, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724461
7.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34062004
8.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33755235
9.
Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients.
Eye Contact Lens
; 47(6): 362-365, 2021 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306485
10.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol
; 21(2): 207-221, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859245
11.
Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation.
Ann Pharmacother
; 54(6): 547-553, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31876431
12.
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Blood
; 130(10): 1189-1197, 2017 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28461396
13.
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.
Haematologica
; 109(2): 682-688, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37675514
14.
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Br J Haematol
; 180(1): 41-51, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29076150
15.
Marizomib for central nervous system-multiple myeloma.
Br J Haematol
; 177(2): 221-225, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28387460
16.
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Br J Haematol
; 174(5): 748-59, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27196567
17.
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Br J Haematol
; 173(6): 884-95, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27071340
18.
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Am J Hematol
; 91(6): 575-80, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26955792
19.
Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study.
Cancer
; 121(7): 1064-70, 2015 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25469920
20.
Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies.
Ann Hematol
; 93(4): 653-60, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24097082